mRNA-1608

· ModernaTX, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for mRNA-1608, covering 2025-05-08 to 2025-05-08. Get the full timeline:

Most recent: Clinical Trial Update: A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes [Phase 1, Phase 2]

See pricing